The prodrug isavuconazonium sulfate (BAL8557) is an extended-spectrum water-soluble triazole, developed for the treatment of severe invasive and life-threatening fungal diseases. Its active moiety, BAL4815, is a potent inhibitor of ergosterol biosynthesis, resulting in the disruption of fungal membrane structure and function. The active compound shows broad-spectrum of activity and potency against all major opportunistic fungi, such as Aspergillus spp., Candida spp., Cryptococcus spp., Mucorales, Black yeasts and their filamentous relatives and the true pathogenic fungi, including Histoplasma capsulatum and Blastomyces dermatitidis. It is currently in Phase III clinical development for treatment of aspergillosis, candidiasis and mucormycosis, as well as other rare fungi infections. We reviewed the pharmacokinetic and pharmacodynamic characteristics of isavuconazole, and its microbiological and clinical investigation progress in advanced stages of development.

, , ,,
Expert Review of Anti-Infective Therapy
Department of Medical Microbiology and Infectious Diseases

Seyedmousavi, S, Verweij, P.E, & Mouton, J.W. (2015). Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases. Expert Review of Anti-Infective Therapy, 13(1), 9–27. doi:10.1586/14787210.2015.990382